Healthcare stocks and the corresponding exchange traded funds continue to spend time in the spotlight as the Republican-controlled Congress moves to replace the Affordable Care Act, also known as Obamacare. Even amid potential political controversy opportunity remains with the S&P 500’s third-largest sector allocation.

The iShares U.S. Healthcare ETF (NYSEArca: IYH) is up 11.1% year-to-date and could offer investors a defensive play with better appreciation potential and less interest rate risk than other defensive sectors.

The pharmaceutical and biotechnology sub-sectors may benefit under a Republican president and Congress as the industries are less at risk of price controls that Democrats vowed to impose. The iShares U.S. Pharmaceuticals ETF (NYSEArca: IHE) is up 6.7% year-to-date. IHE tracks the Dow Jones U.S. Select Pharmaceuticals Index and holds 40 stocks with a significant portion of ETF’s lineup devoted to blue-chip pharmaceuticals such as Pfizer (NYSE: PFE) and Merck (NYSE: MRK).

Healthcare stocks are also showing attractive valuations relative to other defensive sectors, which are richly valued.

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.